Corvus Pharmaceuticals invests $5 million in Angel Pharmaceuticals
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- Wall St slides as oil hovers near $100 on rising Middle East tensions
- Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
- Oil nears $100 as fresh Middle East strikes raise supply risks
- How big a risk are rates to the AI boom?
- 3 reasons why S&P 500 may drop up to 10% in the near term: RBC
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China
June 9, 2026 7:30 AM EDTSOUTH SAN FRANCISCO, Calif., June 09, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it has participated in a new $13.5 million financing for Angel Pharmaceuticals Ltd. (Angel Pharma), the Companys collaboration partner in China. Corvus co-founded Angel Pharma in 2020 to enable the clinical development and commercialization of its pipeline in China as well as the development of other novel drugs. Corvus is Angel Pharmas largest shareholder and is investing $5 million in the current financing.
The funding is anticipated to support Angel Pharmas ongoing... More
